- Home
- ICON vs TIVC Comparison
ICON vs TIVC Comparison
Compare ICON & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICON | TIVC |
|---|---|---|
| Founded | 2023 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 3.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ICON | TIVC |
|---|---|---|
| Price | $1.13 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 112.7K | ★ 222.5K |
| Earning Date | 02-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 4754.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | $22.33 | N/A |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.75 |
| 52 Week High | $4.23 | $5.60 |
Technical Indicators
Market Signals| Indicator | ICON | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 42.03 | 69.31 |
| Support Level | $0.72 | $0.79 |
| Resistance Level | $1.24 | $2.70 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 14.89 | 100.00 |
Price Performance
Historical ComparisonAbout ICON Icon Energy Corp.
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
About TIVC Tivic Health Systems Inc.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.